Erasca (ERAS) Total Current Liabilities (2020 - 2026)
Erasca (ERAS) reported Total Current Liabilities of $26.7 million for Q1 2026, up 4.68% on a YoY basis from $25.5 million in Q1 2025, and down 6.48% quarter-over-quarter from $28.5 million in Q4 2025.
Erasca (ERAS) Total Current Liabilities (2020 - 2026) Analysis & Trends
Erasca has reported Total Current Liabilities for 7 years, with the latest figure at $26.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 4.68% year-over-year to $26.7 million; the trailing twelve-month figure through Mar 2026 stood at $26.7 million (up 4.68% YoY), and the FY2025 full-year result was $28.5 million, down 9.19% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $26.7 million, down from $28.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $48.7 million in Q4 2022, with the low at $21.4 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $28.0 million across 5 years, with a median of $26.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 85.68% — and 2023, when it plunged 46.28%.
- Erasca's Total Current Liabilities stood at $48.7 million in 2022, then slumped by 46.28% to $26.2 million in 2023, then advanced by 20.03% to $31.4 million in 2024, then retreated by 9.19% to $28.5 million in 2025, then fell by 6.48% to $26.7 million in 2026.
- The last three Total Current Liabilities figures came in at $26.7 million (Q1 2026), $28.5 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 26.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.66 Mn |
| Dec 31, 2025 | 28.51 Mn |
| Sep 30, 2025 | 28.71 Mn |
| Jun 30, 2025 | 28.15 Mn |
| Mar 31, 2025 | 25.47 Mn |
| Dec 31, 2024 | 31.40 Mn |
| Sep 30, 2024 | 30.03 Mn |
| Jun 30, 2024 | 24.89 Mn |
| Mar 31, 2024 | 30.24 Mn |
| Dec 31, 2023 | 26.16 Mn |
| Sep 30, 2023 | 26.73 Mn |
| Jun 30, 2023 | 23.29 Mn |
| Mar 31, 2023 | 25.52 Mn |
| Dec 31, 2022 | 48.69 Mn |
| Sep 30, 2022 | 27.68 Mn |
| Jun 30, 2022 | 22.32 Mn |
| Mar 31, 2022 | 21.39 Mn |
| Dec 31, 2021 | 26.22 Mn |
| Sep 30, 2021 | 19.59 Mn |
| Jun 30, 2021 | 17.91 Mn |